NextCure CMO granted options for 14,670 shares

NextCure, Inc. reported that its Chief Medical Officer, Udayan Guha, received an employee stock option grant on January 30, 2026.

Accepted by SEC EDGAR 02/03/2026 - 04:07 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

NextCure, Inc. reported that its Chief Medical Officer, Udayan Guha, received an employee stock option grant on January 30, 2026. The option covers 14,670 shares of common stock at an exercise price of $10.85 per share and is held directly.

One quarter of the option vests on January 30, 2027, with the remaining three quarters vesting in 36 monthly installments starting February 28, 2027. The option expires on January 29, 2036 if not exercised.

Insider Trade Summary

Grant/Award: 14,670 shares

Grant/Award 1 txn

Insider Guha Udayan

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	14,670	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 14,670 contracts (Direct)

Holdings Before and After: Employee Stock Option (Right to Buy), 0 to 14,670 contracts (Direct)

Footnotes (1)

1. F1. One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NextCure (NXTC) disclose in this Form 4?

NextCure disclosed a stock option grant to its Chief Medical Officer. On January 30, 2026, Udayan Guha received an employee stock option for 14,670 shares of common stock at a $10.85 exercise price, reported as directly owned after the transaction.

How many NextCure (NXTC) shares are covered by the new stock option?

The stock option covers 14,670 shares of NextCure common stock. This entire amount was granted on January 30, 2026, and 14,670 derivative securities are shown as beneficially owned following the transaction, all held in direct ownership by the reporting officer.

What is the exercise price and expiration date of the NextCure (NXTC) option grant?

The option has a $10.85 exercise price and expires January 29, 2036. This means the Chief Medical Officer can buy up to 14,670 shares at $10.85 per share any time after vesting, up until the stated expiration date.

What is the vesting schedule for the NextCure (NXTC) stock option granted to the CMO?

The option vests over four years with a back‑loaded schedule. One fourth vests on January 30, 2027. The remaining three fourths vest in 36 equal monthly installments beginning February 28, 2027, tying continued service to incremental vesting.

Who is the reporting person in this NextCure (NXTC) Form 4 filing?

The reporting person is Udayan Guha, Chief Medical Officer of NextCure. The filing identifies him as an officer, not a director or 10% owner, and shows the employee stock option as directly owned following the reported grant transaction.

Was this NextCure (NXTC) Form 4 transaction a purchase of common shares or an option grant?

This filing reports an employee stock option grant, not a direct share purchase. The derivative security is labeled “Employee Stock Option (Right to Buy)” for 14,670 underlying common shares, with no cash price reported for receiving the option itself.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guha Udayan

(Last) (First) (Middle)

C/O NEXTCURE, INC.

9000 VIRGINIA MANOR ROAD, SUITE 200

(Street)

BELTSVILLE MD 20705

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NextCure, Inc. [ NXTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$10.85	01/30/2026		A		14,670		(1)	01/29/2036	Common Stock	14,670	$0	14,670	D

Explanation of Responses:

1. One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027.

	/s/ Steven P. Cobourn, as attorney-in-fact for Udayan Guha	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.